Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single-arm, Open-label, Multicenter Phase II Trial Evaluating the Efficacy and Safety of Ivosidenib Maintenance Therapy After Allogeneic Stem Cell Transplantation (alloSCT) in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Neoplasia (MD) Carrying an IDH1 Mutation

NCT06717958 is registered in ClinicalTrials.gov with Technische Universität Dresden as lead sponsor.

NCT NCT06717958
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06717958 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single-arm, Open-label, Multicenter Phase II Trial Evaluating the Efficacy and Safety of Ivosidenib Maintenance Therapy After Allogeneic Stem Cell Transplantation (alloSCT) in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Neoplasia (MD) Carrying an IDH1 Mutation
Lead sponsor
Technische Universität Dresden
Phase
Phase 2
Overall status
Recruiting
Start date
June 17, 2025
Completion date
February 1, 2030
Enrollment
76 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

aml, mds